Scleroderma Newsroom
ISN News Manager: Jo Frowde
Media Stories
Scleroderma Archive
2016: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2018 - 2017 - 2016 - 2015

March 2016 Scleroderma News

Cytori’s phase III scleroderma trial achieves progress. Cytori Therapeutics, a biotechnology company, said its U.S. FDA approved Phase 3 STAR trial has enrolled and treated its 40th patient, or 50% of target enrollment., 03/25/2016. (Also see Scleroderma Clinical Trials)

Cytori Granted SME Status by European Medicines Agency The European Medicines Agency’s (EMA) Micro, Small and Medium-sized Enterprise (SME) office has granted SME status to Cytori Therapeutics. Business Wire, 03/23/2016. (Also see Scleroderma Clinical Trials)

Systemic sclerosis (SSc) is associated with a unique colonic microbial consortium. This study demonstrates a distinct colonic microbial signature in SSc patients and this unique ecological change may perpetuate immunological aberrations and contribute to clinical manifestations of SSc. PubMed, Arthritis Rheumatol, 01/08/2016. (Also see Bowel Dysfunction)

Does the clinical context improve the reliability of rheumatologists grading digital ulcers (DU) in systemic sclerosis? The overall intra and inter–rater reliability of DU grading did not significantly improve with the clinical context and agreement between patients and rheumatologists was poor. PubMed, Arthritis Care Res (Hoboken), 01/08/2016. (Also see Digital Ulcers)

Factors associated with development of gastrointestinal problems in patients with scleroderma: a systematic review. Longitudinal observational studies are warranted, as there is insufficient evidence to describe the risk factors for GI problems in patients with scleroderma. PMC, 12/30/2015. (Also see Gastrointestinal Involvement)

Topical Paste May Prevent Skin Hardening in Scleroderma Patients. This treatment also has therapeutic potential for other collagen–related diseases, including scleroderma and interstitial pulmonary fibrosis. Scleroderma News, 01/12/2016. (Also see Skin Fibrosis)

Scleroderma–related Interstitial Lung Disease (SSc–ILD) Not Linked to Idiopathic Interstitial Pneumonia. The study confirmed that SSc–ILD and idiopathic interstitial pneumonia are different diseases, not sharing a genetic basis. Scleroderma News, 02/02/2016. (Also see Pulmonary Fibrosis Research and Lung Involvement)

Connective tissue diseases: Nucleosomes and systemic sclerosis (SSc). New observations suggest that nucleosomes can mediate both IgG production and B–cell proliferation, via Toll–like receptor signalling, and thereby affect the pathogenesis of SSc. Nature Reviews Rheumatology, 02/04/2016. (Also see B Cells and T Cells)

Genetic and epigenetic abnormalities in systemic sclerosis (SSc). Further investigations of the interplay between genetics and epigenetics will be beneficial to elucidate the complex molecular cross–talk and heterogeneity in the SSc pathogenesis. PubMed, J Dermatol, 2016 Jan;43(1):10-8. (Also see Genetics)

Interstitial Lung Disease in Systemic Scleroderma, Complicated with Bilateral Pulmonary Aspergilloma: An Unusual Association. Management of aspergilloma in a background of extensive interstitial lung disease remains poorly defined and complicated and overall prognosis is unfavourable. PubMed, J Clin Diagn Res, 2015 Dec;9(12):OD11-3. (Also see Correlation between Pulmonary Fibrosis and other Diseases or Complications)

Current Approaches to the Treatment of Systemic–Sclerosis–Associated Pulmonary Arterial Hypertension (SSc–PAH). This review describes the current management of SSc–PAH with an emphasis on the impact of the different organ involvements in the prognosis and treatment response. PubMed, Curr Rheumatol Rep, 2016 Jan;18(2):10. (Also see Treatments for Pulmonary Hypertension)

Sex disparities in systemic sclerosis (SSc)–associated pulmonary arterial hypertension (PAH): a cohort study. Sex disparities appear to exist in the frequency of PAH, time to PAH diagnosis, PAH disease duration and SSc disease burden. PubMed, Arthritis Res Ther, 2016 Jan 27;18(1):30. (Also see Prognosis of Pulmonary Hypertension in Systemic Sclerosis)

Go to Scleroderma Medical News: February 2016

Giving Assistant
United Way of Central New Mexico
United Way of Snohomish County
See ISN News for recent donors, including Pam Hop, Margaret Roof, Winifred Schillberg, Arnold Slotkin, and Juliet Youkhana. Plus donations in honor of Kim Thwaits, and in loving memory of Marta Marx, Jim Miller, and Arlene Marie Petulla.
Click Here to Donate or Shop
or click on the floating green DONATE button.


TOLL FREE HOTLINE, U.S. and Canada: 1-800-564-7099
Ask for our Free Info Packet by email or postal mail!

SCLERO.ORG is the world leader for trustworthy research, support, education and awareness for scleroderma and related illnesses, such as pulmonary hypertension. We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, or Volunteer. Donations may also be mailed to:

International Scleroderma Network (ISN)
7455 France Ave So #266
Edina, MN 55435-4702 USA
Email [email protected] to request our Welcome email, or to report bad links or to update this page content. Privacy Policy.

The most important thing in the world to know about scleroderma is!

Donate Now
Copyright 1998-2018, International Scleroderma Network. AKA Scleroderma from A to Z and SCLERO.ORG. All Rights Reserved.